| Revenue growth | FY26 +6% YoY; Q4 ex-gRevlimid +15.3% YoY. |
|---|---|
| Margins | EBITDA margin at 20.4%; guided >21% for FY27. |
| Demand visibility | Sustained momentum in regulated markets; stable volumes. |
| Management confidence | Bullish on US $2bn target and Europe €1bn base. |
Growth
FY26 revenue grew 6% YoY (9.5% ex-gRevlimid); Q4 FY26 revenue reached ₹8,853cr with Net Profit up 2% to ₹921cr.
Outlook
FY27 EBITDA margin guided north of 21%. US business aiming for $2bn revenue milestone near-term via Lannett acquisition.
Risks
Higher operating costs from power/fuel; seasonality in US sales; geopolitical issues; pricing pressures in biosimilars.
Earnings Call filed with BSE, NSE: AUROPHARMA. Summary written with AI assistance from the document.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,712.00
- Market cap
- ₹99,433 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 25.2×Sector 50.4×
- Promoter holding
- 51.88%+0.06% QoQ
- FII holding
- 16.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Regulatory Approval
Aurobindo Pharma received USFDA final approval for its first MDI product, Beclomethasone Dipropionate HFA Inhalation Aerosol. The US market for this segment is estimated at US$301 million.
Aurobindo Pharma Acquisition Worth ₹9.47 Cr
Aurobindo Pharma's subsidiary acquired A1 Biochem USA Inc for ₹9.47 Crore. This 100% acquisition expands its contract research and development services capabilities in the USA.
- Value
- ₹9.47 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹9.5 Cr
Aurobindo Pharma's subsidiary, A1 Biochem Labs (India), invested USD 1,000,000 (approx. ₹9.5 Crore) to incorporate and capitalize a new US subsidiary, A1 Biochem USA Inc.
- Value
- ₹9.50 Cr
Aurobindo Pharma Business Update
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma Earnings Call Transcript: Key Takeaways
Q1FY27 revenue grew 16% YoY to ₹9,150 Cr. EBITDA margin stood at 21% with PAT of ₹1,032 Cr. Focus remains on complex generics, Lannett integration, and biosimilar monetization.
- Call
- Guides 10% growth
Aurobindo Pharma Investor Presentation: Key Takeaways
Aurobindo reported strong Q1FY27 performance with revenue up 16.3% YoY to ₹9,150 Cr and PAT up 25.2% to ₹1,032 Cr, driven by US base business volume gains and European expansion.